GSK Pharma slips 5% after halting sale of acidity medicine Zinetac, other ranitidine products The company has made the decision to initiate a voluntary recall of Zinetac Tablets 150 mg and 300 mg products manufactured in India.
Government scrambles to address shortage of rabies vaccine after GSK exit Sources within the vaccine industry said that one of the main reasons for the current shortage was due to the exit of Chiron Behring Vaccines, a unit of GlaxoSmithKline (GSK).
Focus on selective products, therapies starting to pay dividends: GSK Pharma Vaidheesh hinted at new launches such as a vaccine (Bexsero) to protect infants against Meningitis B and a new drug to treat autoimmune disorders
Hold GlaxoSmithKline Consumer Healthcare; target of Rs 7972: Prabhudas Lilladher Prabhudas Lilladher recommended hold rating on GlaxoSmithKline Consumer Healthcare with a target price of Rs 7972 in its research report dated August 05, 2019.
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.